Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q3 FY26 Earnings Presentation
28 slides from Piramal Pharma's earnings presentation, Jan 29, 2026
Slide 1: Exchange cover letter: Press Release and Investor Presentation
28th January, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Press Release and Investor Presentation – Unaudited Financi
Slide 2: Piramal Pharma Limited Announces Results for Q3 and 9M FY26
PRESS RELEASE Piramal Pharma Limited Announces Results for Q3 and 9M FY26 Mumbai, India | January 28, 2026: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quart
Slide 3: Key Business Highlights for Q3/9M FY26
Key Business Highlights for Q3/9M FY26 Contract Development and Manufacturing Organization (CDMO): - Biopharma funding in H2CY25 has shown signs of recovery with funding in H2CY25 close to double vs. H1CY25 and higher by over 50% vs H2CY24. Although, on full year basis CY25 funding was flat vs. CY24
Slide 4: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement (in ₹ Crores or as stated) Quarterly Nine Months Particulars Q3FY26 Q3FY25 YoY % Q2FY26 QoQ % 9MFY26 9MFY25 YoY % Revenue from Operations 2,140 2,204 (3)% 2,044 5% 6,117 6,397 (4)% Other Income 43 12 256% 66 (34)% 167 93 80% Total Income 2,183 2,216 (2)% 2,109
Slide 5: Q3 and 9M FY26 Earnings Conference Call
Q3 and 9M FY26 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 29th January 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q3 and 9M FY26 Results. The dial-in details for the call are as under: Event Location & Time Telephone Number +
Slide 6: Q3FY26 Results
Q3FY26 Results Piramal January 2026 Pharma Limited
Slide 7: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner,
Slide 8: Piramal Pharma – A Diversified Global Pharma & Wellness Company
Piramal Pharma – A Diversified Global Pharma & Wellness Company A Portfolio of Differentiated Products and Services, and Commercial Presence in 100+ Countries CDMO Business Complex Hospital Generics Business Consumer Healthcare Business Integrated CDMO Company A Critical Care Company Consumer Health
Slide 9: Performance Highlights
Performance Highlights
Slide 10: Key Financial Highlights – Q3 / 9M FY26
Key Financial Highlights – Q3 / 9M FY26 Revenue from Operations EBITDA & EBITDA Margin Summary (In ₹ Crore) (EBITDA: In ₹ Crore) EBITDA Margin Revenue and EBITDA growth during Q3 and 9M FY26 was impacted by: (4)% 15% 10% • Inventory destocking in one large on-patent commercial product by customer. •
Slide 11: CDMO: Strengthening Our Core
Strengthening Our Core Despite a Challenging Year, We Continue to Build on Our Strengths for a Stronger Future Key Initiatives Taken Investing In High Growth Enhanced our Business Strengthened Execution Continued Focus on Areas Development team Across Network Quality & Sustainability CDMO Investing
Slide 12: Strengthening Our Core (PCH)
Strengthening Our Core Despite a Challenging Year, We Continue to Build on Our Strengths for a Stronger Future Key Initiatives Taken Continued to Invest in Our Expanding Reach into Tier 3/4 Optimizing Portfolio and Power Brands Towns Distribution Channel Mix PCH Strong growth of 20%+ in Power Brands
Slide 13: Business Wise Performance
Business Wise Performance
Slide 14: CDMO Business
CDMO Business Performance Highlights Revenue Growth (In ₹ Crore) Biopharma funding showing signs of improvement (12)% (9)% • Strong recovery in biopharma funding in H2CY25 - Funding in H2CY25 was close to double vs. H1CY25 and higher by over 50% vs. H2CY24. (Source: Industry Reports) • Although, o
Slide 15: Maintaining our Best-in-Class Quality Track Record
Maintaining our Best-in-Class Quality Track Record 400+ Regulatory Inspections with no OAI 150+ Audits Annually by Customers Regulatory Inspections (Ex US FDA) US FDA Inspections 44 197 167 163 172 165 170 2 35 36 36 36 157 140 141 148 142 29 29 30 26 27 4 4 2 115 25 24 3 2 99 17 5 5 3 42 1 35 32 32
Slide 16: US Expansion on Track – Seeing Good Customer Interest
US Expansion on Track – Seeing Good Customer Interest Steadily Increasing our Footprint in the US US$ 90Mn investment to expand Lexington and Riverview facilities, on Our Presence in the US track. Seeing good customer interest for our North America (NA) sites. Our NA sites with differentiated capabi
Slide 17: Complex Hospital Generics Business
Complex Hospital Generics Business Performance Highlights Revenue Growth (In ₹ Crore) Inhalation Anesthesia 1% 2% • US - Continue to grow ahead of the market and maintain #1 Rank in Sevoflurane with value market share of 47% - up from 44% in Mar’24. (Source:- IQVIA) • Ex-US Markets – Initiated Sev
Slide 18: Agreement to Acquire Kenalog® from Bristol-Myers Squibb
Agreement to Acquire Kenalog® from Bristol-Myers Squibb Complex Product with Limited Competition and Healthy EBITDA margins – A Good Fit for Our CHG Portfolio Entered into an agreement to acquire Kenalog® from Bristol-Myers Squibb Company in an all-cash deal for upfront consideration of US$ 35Mn, an
Slide 19: Piramal Consumer Healthcare Business
Piramal Consumer Healthcare Business Performance Highlights Revenue Growth (In ₹ Crore) Strong growth of 20%/16% in Q3 and 9M FY26 – faster than market 16% 20% Power Brands grew strength to strength at 30%/23% in Q3 and 9MFY26 • Contributing 51% to total PCH sales in 9M FY26 • Growth was driven
Slide 20: Focus on Power Brands with Brand Promotion and Marketing
Focus on Power Brands with Brand Promotion and Marketing (In ₹ Cr) Investments in Brand Promotion and Marketing % of PCH 15% 13% 11% 12% 12% sales 131 131 125 98 110 FY23 FY24 FY25 9MFY25 9MFY26 (In ₹ Cr) Strong Growth in our Power Brands 21% CAGR 23% 538 487 370 448 396 FY23 FY24 FY25 9MFY25 9MFY26
Slide 21: Joint Venture with AbbVie
Joint Venture with AbbVie AbbVie Therapeutics India Private Limited, a joint venture between AbbVie and PPL, is one of the market leaders in the Indian ophthalmology therapy area Ownership Ownership 49% 51% In FY2025, the JV reported revenue of ₹494 Cr. with PAT margin of 28% Brand Lumigan Combigan
Slide 22: Financials
Financials
Slide 23: Consolidated Financials Highlights
Consolidated Financials Highlights (in ₹ Cr. or as stated) Particulars Q3FY26 Q3FY25 YoY Change Q2FY26 QoQ Change 9MFY26 9MFY25 YoY Change Revenue from Operations1 2,140 2,204 (3)% 2,044 5% 6,117 6,397 (4)% CDMO 1,166 1,278 (9)% 1,044 12% 3,207 3,659 (12)% CHG 668 654 2% 644 4% 1,948 1,928 1% PCH 33
Slide 24: Sustainability
Sustainability
Slide 25: Strengthening Sustainability Performance - External Validation
Strengthening Sustainability Performance - External Validation Rising Sustainability scores reflect consistent execution against science-based targets and responsible operations Sustainability Ratings: Demonstrated Improvement & Expanding Coverage Science–Based Targets initiative (SBTi Approved) SBT
Slide 26: Embedding Sustainability in Every Step of Our Growth
Embedding Sustainability in Every Step of Our Growth Responsible Operations Zero 2.10 Lakh 10.5% 14.08% Hazardous Waste to Landfill Kiloliters of Freshwater Reduction in Scope 1 & 2 Total Energy Sourced from Bio- Saved Emissions Over Base Year Briquettes/Biomass (FY22) Business Resilience 50% 100% 2
Slide 27: Dial-in Details for Q3 and 9M FY26 Earnings Conference Call
Dial-in Details for Q3 and 9M FY26 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 09:30 AM IST 1 800 120 1221 (Toll free number) USA – 11:00 PM Toll free number Conference call (Eastern Time – New York) 18667462133 on 29th
Slide 28: For Investor Queries
For Investor Queries: Gagan Borana Madhusudan Dalmia Investor Relations and Enterprise Risk Management Investor Relations Email: gagan.borana@piramal.com Email: madhusudan.dalmia@piramal.com Our Websites:- Piramal Pharma Limited CDMO www.piramalpharma.com www.piramalpharmasolutions.com Complex Hospi